Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Critical Care Medicine(Electronic Edition) ›› 2022, Vol. 15 ›› Issue (05): 372-378. doi: 10.3877/cma.j.issn.1674-6880.2022.05.004

• Original Article • Previous Articles     Next Articles

Clinical efficacy of noninvasive high-frequency oscillation ventilation in premature infants with respiratory distress syndrome

Ruizhi Dai1,(), Meichi Huo1, Zheng Li1   

  1. 1. Department of Neonatology, Cangzhou Women & Children's Healthcare Hospital, Cangzhou 061001, China
  • Received:2022-02-25 Online:2022-10-31 Published:2023-01-09
  • Contact: Ruizhi Dai

Abstract:

Objective

To evaluate the effect of noninvasive high-frequency oscillation ventilation (nHFOV) in premature infants with respiratory distress syndrome (RDS).

Methods

A total of 200 premature infants with RDS from March 2017 to March 2020 were randomly divided into a research group and a control group, with 100 cases in each group. The research group was treated with nHFOV and the control group was treated with nasal continuous positive airway pressure. The effective rate, failure rate of initial treatment, incidence of bronchopulmonary dysplasia (BPD), incidence of adverse events, blood gas analysis related indicators, amplitude integrated electroencephalogram (aEEG) score and high mobility group protein B1 (HMGB1) level were compared between the two groups.

Results

The effective rate was much better in the research group than in the control group [93.00% (93/100) vs. 63.0% (63/100), χ2 = 68.923, P <0.001]. The failure rate of initial treatment [6.00% (6/100) vs. 15.00% (15/100), χ2 = 4.310, P = 0.038] and the incidence of BPD [1.00% (1/100) vs. 9.00% (9/100), χ2 = 6.737, P = 0.009] in the research group were much lower than those in the control group. There was no significant difference in the incidence of adverse events such as pneumothorax/air leakage, gastrointestinal perforation, necrotizing enterocolitis, retinopathy of prematurity, intracranial hemorrhage, nasal injury and death between the two groups (χ2 = 2.083, 2.909, 0.977, 1.332, 1.047, 0.521, 2.750; all P > 0.05). The levels of partial pressure of oxygen [(89 ± 28) mmHg vs. (80 ± 29) mmHg, t = 2.151, P = 0.033], partial pressure of carbon dioxide [(37 ± 7) mmHg vs. (41 ± 10) mmHg, t = 3.386, P<0.001] and oxygen saturation [(97.4 ± 2.1)% vs. (90.6 ± 6.4)%, t = 10.049, P<0.001] significantly improved, the aEEG score remarkedly increased [(8.5 ± 1.5) vs. (5.2 ± 1.9), t = 13.319, P<0.001], and the serum HMGB1 level obviously decreased [(578 ± 71) ng/L vs. (628 ± 72) ng/L, t = 5.071, P<0.001] in the research group after treatment, as compared with the control group.

Conclusion

The nHFOV can effectively improve brain function, blood gas indicators and respiratory support related indexes, reduce serum HMGB1 levels and enhance overall clinical efficacy in premature infants with RDS.

Key words: Respiratory distress syndrome, newborn, Infant, premature, High-frequency ventilation

京ICP 备07035254号-20
Copyright © Chinese Journal of Critical Care Medicine(Electronic Edition), All Rights Reserved.
Tel: 0571-87236467 E-mail: zhwzzyxzz@126.com
Powered by Beijing Magtech Co. Ltd